Wasting Syndrome (Cachexia) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 Cachexia is a complex metabolic syndrome that arises from an underlying illness and is characterized by the loss of muscle mass, with or without the loss of fat mass. It often presents with anorexia, an inflammatory process, insulin resistance, and increased protein turnover. Cachexia leads to weight loss and an elevated risk of mortality. The primary cause of cachexia is an excess of cytokines. Additional contributing factors include deficiencies in testosterone and insulin-like growth factor-I, overabundance of myostatin, and excess glucocorticoids. Cachexia is distinguished by a persistent increase in the body's basal metabolic rate that is not compensated by an adequate intake of calories and protein. Various factors contribute to this abnormal metabolic cascade, including digestive issues, tumor-related factors, and hormonal responses to the underlying disease. Digestive factors that contribute to poor intake include dysgeusia (distorted sense of taste), nausea, dysphagia (difficulty swallowing), mucositis (inflammation of the mucous membranes), and constipation.

·       Cachexia is categorized into pre-cachexia, cachexia, and refractory cachexia. The consensus definitions for these stages are as follows:

·       Pre-cachexia: characterized by a weight loss of more than 1kg but less than 5%

·       Cachexia: indicated by a weight loss of more than 5% or a weight loss of more than 2% with a body mass index (BMI) below 20kg/m^2

·       Refractory cachexia: defined by a weight loss of more than 15% with a BMI below 23kg/m^2 or a weight loss of more than 20% with a BMI below 27kg/m^2

·       Differential diagnoses for cachexia include the following conditions: Celiac disease, Crohn's disease, Cystic fibrosis, Dementia, Mercury poisoning, Motor neuron disease, Multiple sclerosis, Multiple systems, trophy, Parkinson's disease, and Rheumatoid arthritis.

·       The prevalence of cancer cachexia in the USA was reported to range between 11,300 (0.4 per 10,000, gastric cancer) and 92,000 patients (2.9 per 10,000, lung cancer).

Thelansis’s “Wasting Syndrome (Cachexia) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Wasting Syndrome (Cachexia) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Wasting Syndrome (Cachexia) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Wasting Syndrome (Cachexia) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Wasting Syndrome (Cachexia) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032